Device Trial Radar · NCT06649097
Clearance of Intracranial Blood Products by Continuous Irrigation With the IRRAflow System
Last checked: Nov 19, 2026Latest source record: Oct 28, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
250
Planned (sponsor's estimate)
Start
Sep 25, 2025
Primary completion
Jan 2031
Study completion Jul 2031
Sponsor
- Lead sponsor
- Christopher P KellnerAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- IRRAS
- First posted
- Oct 18, 2024
Design
- Study type
- Observational
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The study is a multi-center prospective cohort, controlled, phase 4 post-market registry evaluating the efficacy and radiographic outcomes associated with the use of the IRRAflow® Active Fluid Exchange System compared to standard of care external ventricular drains.
Conditions
- Intracranial Hemorrhage
- Ventriculitis
- Intracranial Abscess
Interventions
IRRAflow® CNS (Active Fluid Exchange) SystemDevice
The IRRAflow system offers automated irrigation, controlled drainage and intracranial pressure (ICP) monitoring all in one system. It consists of three main parts - IRRAflow 2.0 Catheter, IRRAflow Tube Set, IRRAflow Control Unit.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Residual blood volume by post bleed day 5Time frame: Post-procedure day 5
- Utility weighted modified Rankin ScoreTime frame: End of study, at 6 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Icahn School of Medicine at Mount Sinai
New York, New York · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.